about
Pharmacologic resistance in colorectal cancer: a reviewBiomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Fucoidan as a marine anticancer agent in preclinical developmentMicroRNA-192 suppresses liver metastasis of colon cancer.Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasisDual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis.Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabGenetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells.Role of targeted agents in metastatic colorectal cancer.MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.Recruitment of CD11b+Ly6C+ monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody.Targeted therapy: resistance and re-sensitization.Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer.Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer.Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1)
P2860
Q26769850-E84FAAE6-305A-41FA-8F47-EB4F101805E2Q27853358-43487FFB-4680-467B-8A0D-C6A7C4FAAC94Q28397061-4AEE2441-A794-4A76-8DB9-74440693E347Q33594662-F9F6C064-4BE5-4F8C-A89C-70D2AD38B4D5Q33618582-A4506136-2AAB-4970-AC76-1014367E51EBQ34537725-D7041500-F038-4F5B-BC4B-F3980E4577E4Q34639841-3C3F5058-221B-4997-AD37-1B4371470E2CQ34747015-E526CF5E-CB82-4CC1-9C35-BDAF52669F02Q34825323-0B0B0929-2CAF-405E-81FC-4B78FA72C789Q35637857-FBE91431-6CFE-4F15-A57F-BAC3B6CE5517Q35780797-A12482D3-3193-4610-BC40-14615E8DEF05Q35929796-2A1AE79C-E03D-4B25-9B92-6FCE84C369BEQ36286833-A6A72578-508D-45F0-B511-02DAD7BAFE9BQ37589238-FFD678A2-8598-4B59-9A53-59374BE37F9DQ38104294-A1178133-214D-4E04-BBF9-DAC83B1AF8D2Q38247982-D431260B-A079-46B9-9A29-08C391D06DD5Q38969661-D1389726-5686-4AF5-A37F-9EF751E842DFQ39044411-3DFB99EA-3177-4898-B667-AD63680B2661Q40978947-921D269E-9B62-4F60-BB3A-31696D08C8ABQ41356511-A5FC5432-E469-4536-92A7-2B948FEEEB5DQ43062212-B2EC0C10-2C8B-4E5E-9093-2158D6DB4176Q55280505-D44735AB-B25C-4CEB-B193-D0B9E7847053Q55456514-0AC3CA7F-4B6B-4D3F-B4BA-76C77C995A75Q57041735-527ABE69-E813-4B53-ADC6-041F4786FCF2
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overcoming resistance to antiangiogenic therapies.
@en
type
label
Overcoming resistance to antiangiogenic therapies.
@en
prefLabel
Overcoming resistance to antiangiogenic therapies.
@en
P2860
P1433
P1476
Overcoming resistance to antiangiogenic therapies.
@en
P2093
Hans Prenen
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0068
P577
2012-07-06T00:00:00Z